Great Lakes Advisors LLC Buys 2,975 Shares of United Therapeutics Corporation $UTHR

Great Lakes Advisors LLC boosted its stake in United Therapeutics Corporation (NASDAQ:UTHR) by 194.7% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,503 shares of the biotechnology company’s stock after acquiring an additional 2,975 shares during the quarter. Great Lakes Advisors LLC’s holdings in United Therapeutics were worth $1,888,000 as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in UTHR. Chung Wu Investment Group LLC acquired a new position in shares of United Therapeutics during the second quarter worth about $29,000. WealthCollab LLC lifted its stake in United Therapeutics by 55.9% in the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock valued at $30,000 after acquiring an additional 38 shares in the last quarter. Rakuten Securities Inc. boosted its position in United Therapeutics by 76.7% during the 2nd quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 46 shares during the last quarter. Wilmington Savings Fund Society FSB grew its stake in shares of United Therapeutics by 125.6% during the 3rd quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock worth $37,000 after acquiring an additional 49 shares in the last quarter. Finally, Geneos Wealth Management Inc. raised its holdings in shares of United Therapeutics by 141.7% in the first quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock valued at $45,000 after purchasing an additional 85 shares during the last quarter. Institutional investors own 94.08% of the company’s stock.

United Therapeutics Trading Up 0.4%

Shares of NASDAQ UTHR opened at $469.49 on Friday. The firm has a market cap of $20.22 billion, a P/E ratio of 17.79, a price-to-earnings-growth ratio of 2.49 and a beta of 0.84. The business’s 50 day moving average is $487.26 and its 200-day moving average is $421.02. United Therapeutics Corporation has a 1-year low of $266.98 and a 1-year high of $519.99.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, October 29th. The biotechnology company reported $7.16 earnings per share for the quarter, topping the consensus estimate of $6.89 by $0.27. United Therapeutics had a net margin of 40.65% and a return on equity of 18.83%. The business had revenue of $799.50 million during the quarter, compared to analysts’ expectations of $812.87 million. During the same quarter in the previous year, the company earned $6.39 EPS. The business’s revenue was up 6.8% on a year-over-year basis. Analysts forecast that United Therapeutics Corporation will post 24.48 EPS for the current year.

Analysts Set New Price Targets

Several brokerages recently commented on UTHR. HC Wainwright increased their target price on shares of United Therapeutics from $500.00 to $525.00 and gave the stock a “buy” rating in a report on Thursday, October 30th. UBS Group boosted their price target on shares of United Therapeutics from $600.00 to $645.00 and gave the stock a “buy” rating in a research report on Tuesday, January 6th. Wells Fargo & Company increased their price objective on shares of United Therapeutics from $414.00 to $423.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 30th. Royal Bank Of Canada lifted their target price on United Therapeutics from $569.00 to $587.00 and gave the company an “outperform” rating in a research report on Thursday, October 30th. Finally, Morgan Stanley set a $447.00 target price on United Therapeutics in a report on Wednesday, October 29th. Eight investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $509.50.

Insider Activity

In other United Therapeutics news, EVP Paul A. Mahon sold 8,300 shares of the company’s stock in a transaction on Thursday, January 15th. The stock was sold at an average price of $469.89, for a total transaction of $3,900,087.00. Following the completion of the sale, the executive vice president directly owned 36,781 shares in the company, valued at $17,283,024.09. This represents a 18.41% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Christopher Causey sold 1,000 shares of the company’s stock in a transaction on Tuesday, January 6th. The stock was sold at an average price of $510.00, for a total value of $510,000.00. Following the sale, the director owned 4,190 shares of the company’s stock, valued at approximately $2,136,900. This represents a 19.27% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders sold 566,864 shares of company stock worth $269,514,607. 10.30% of the stock is currently owned by company insiders.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.